Understanding histone deacetylases in the cancer development and treatment: An epigenetic perspective of cancer chemotherapy

DNA and Cell Biology

Volumn 31, Issue SUPPL. 1, 2012, Pages

  Ahmad, Mudassier ^a   Hamid, Abid ^a   Hussain, Aashiq ^a   Majeed, Rabiya ^a   Qurishi, Yasrib ^a   Bhat, Javeed Ahmad ^a   Najar, Rauf Ahmad ^a   Qazi, Asif Khurshid ^a   Zargar, Mohmmad Afzal ^b   Singh, Shashank Kumar ^a   Saxena, Ajit Kumar ^a  

^a CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

^b UNIVERSITY OF KASHMIR   (India)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; BELINOSTAT; DACINOSTAT; ENTINOSTAT; GIVINOSTAT; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PANOBINOSTAT; PIVALOYLOXYMETHYL BUTYRATE; ROMIDEPSIN; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ACETYLATION; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRAIN CANCER; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER PREVENTION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; COLORECTAL CANCER; DIETARY INTAKE; DNA BINDING; DNA REPAIR; DRUG APPROVAL; DRUG STRUCTURE; ENZYME ACTIVITY; EPIGENETICS; EUCHROMATIN; GENE EXPRESSION; HETEROCHROMATIN; HISTONE MODIFICATION; HUMAN; LEUKEMIA; LIVER CANCER; LUNG CANCER; LYMPHOMA; MELANOMA; MESOTHELIOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; NUCLEOSOME; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; T CELL LYMPHOMA; TRANSCRIPTION REGULATION;

ACETYLATION; DRUG THERAPY; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; NEOPLASMS;

EID: 84866550710     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2011.1575     Document Type: Review

References (49)

1. Ahn, M.Y., Jung, J.H., Na, Y.J., and Kim, H.S. (2008). A natural histone deacetylase inhibitor, Psammaplin, A., induces cell cycle arrest and apoptosis in human endometrial cancer cells. Gynecol Oncol 108, 27-33. (Pubitemid 350299431)
2. Bertino, E.M., and Otterson, G.A. (2011). Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin Investig Drugs 20, 1151-1158.
3. Bolden, J.E., Peart, M.J., and Johnstone, R.W. (2006). Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5, 769-784. (Pubitemid 44348499)
4. Bradner, J.E., West, N., Grachan M.L., et al. (2010). Chemical phylogenetics of histone deacetylases. Nat Chem Biol 6, 238-243.
5. Chang, S., McKinsey, T.A., Zhang, C.L., Richardson, J.A., Hill, J.A., and Olson, E.N. (2004). Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 24, 8467-8476. (Pubitemid 39245069)
6. Christensen, D.P., Dahllö f, M., Lundh, M., Rasmussen, D.N., Nielsen, M.D., Billestrup, N., Grunnet, L.G., and Mandrup-Poulsen, T. (2011). Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. Mol Med 17, 378-390.
7. Cohen, H.Y., Lavu, S., Bitterman, K.J., Hekking, B., Imahiyerobo, T.A., Miller, C., Frye, R., Ploegh, H., Kessler, B.M., and Sinclair, D.A. (2004). Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 13, 627-638. (Pubitemid 38368121)
8. Dashwood, R.H., and Ho E. (2007). Dietary histone deacetylase inhibitors: from cells to mice to man. Semin Cancer Biol 17, 363-369. (Pubitemid 47369168)
9. Deribe, Y.L., Pawson, T., and Dikic I. (2010). Post-translational modifications in signal integration. Nat Struct Mol Biol 17, 666-672.
10. Dokmanovic, M., Clarke, C., and Marks, P.A. (2007). HDAC Inhibitors: Overview and perspectives. Mol Cancer Res 5, 981-989.
11. Dowdy, S.C., Jiang, S., Zhou, X.C., Hou, X., Jin, F., Podratz, K.C., and Jiang, S.W. (2006). Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther 5, 2767-2776. (Pubitemid 44849003)
12. Druesne, N., Pagniez, A., and Mayeur C. (2004). Diallyl disulfide (DADS) increases histone acetylation and p21waf1/cip1 expression in human colon cancer cell lines. Carcinogenesis 25, 1227-1236. (Pubitemid 38968051)
13. Esteller, M. (2008). Epigenetics in cancer. N Eng J Med 358, 1148-1159.
14. Gao, L., Cueto, M.A., Asselbergs, F., and Atadja, P. (2002). Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 277, 25748-25755. (Pubitemid 34951896)
15. Glozak, M.A., Sengupta, N., Zhang, X., and Seto E. (2005). Acetylation and deacetylation of non-histone proteins. Gene 363, 15-23. (Pubitemid 41691888)
16. Gregory, P.D., Schmid, A., Zavari, M., Munsterkotter, M., and Horz W. (1999). Chromatin remodelling at the PHO8 promoter requires SWI-SNF and SAGA at a step subsequent to activator binding. EMBO J 18, 6407-6414. (Pubitemid 29533244)
17. Guardiola, A.R., and Yao, T.P. (2002). Molecular cloning and characterization of a novel histone deacetylase HDAC10. J Biol Chem 277, 3350-3356. (Pubitemid 34953202)
18. Haberland, M., Montgomery, R.L., and Olson, E.N. (2009). The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10, 32-42.
19. Hertel, C.B., Langst, G., Hö rz, W., and Korber P. (2005). Nucleosome stability at the yeast PHO5 and PHO8 promoters correlates with differential cofactor requirements for chromatin opening. Mol Cell Biol 25, 10755-10767. (Pubitemid 41747121)
20. Jacobson, R.H., Ladurner, A.G., King, D.S., and Tjian R. (2000). Tandem bromodomains in the chromatin remodeler RSC recognize acetylated histone H3 Lys14. Science 288, 1422-1425.
21. Jones, P.A., and Baylin, S.B. (2007). The epigenomics of cancer. Cell 128, 683-692. (Pubitemid 46273572)
22. Jones, P.L., Veenstra, G.J., Wade, P.A., Vermaak, D., Kass, S.U., Landsberger, N., Strouboulis, J., and Wolffe, A.P. (1998). Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19, 187-191. (Pubitemid 28248804)
23. Kelly, W.K., Connor, O.A., Krug, L.M., Chiao, J.H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J.P., Schwartz, L., Richardson, S., Chu, E., Olgac, S., Marks, P.A., Scher, H., and Richon, V.M. (2005). Phase I study of an oral histone deacetylase inhibitor,suberoylani lide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23, 3923-3931. (Pubitemid 46218695)
24. Kim, Y.B., Lee, K.H., Sugita, K., and Yoshida, M., Horinouchi S. (1999). Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 18, 2461-2470. (Pubitemid 29206159)
25. Kraker, A.J., Mizzen, C.A., Hartl, B.G., Miin, J., Allis, C.D., and Merriman R.L. (2003). Modulation of histone acetylation by [4-(acetylamino)-N- (2-amino-phenyl) benzamide] in HCT-8 colon carcinoma. Mol Cancer Ther 2, 401-408.
26. Kuendgen, A., Strupp, C., Aivado, M., et al. (2004). Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104, 1266-1269. (Pubitemid 39166498)
27. Kurdistani, S.K., and Grunstein, M. (2003). Histone acetylation and deacetylation in yeast. Nat Rev Mol Cell Biol 4, 276-284. (Pubitemid 36383954)
28. Leoni, F., Fossati, G., Lewis, E.C., Lee, J.K., Porro, G., Pagani, P., Modena, D., Moras, M.L., Pozzi, P., Reznikov, L.L., Siegmund, B., Fantuzzi, G., Dinarello, C.A., and Mascagni P. (2005). The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 11, 1-15.
29. Luger, K., Mader, A.W., Richmond, R.K., Sargent, D.F., and Richmond, T.J. (1997). Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389, 251-260. (Pubitemid 27406632)
30. Ma, W.W., and Adjei, A.A. (2010). Novel agents on the horizon for cancer therapy. CA Cancer J Clin 59, 111-137.
31. Minucci, S., and Pelicci, P.G. (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6, 38-51. (Pubitemid 43054973)
32. Myzak, M.C., Dashwood, W.M., Orner, G.A., Ho, E., and Dashwood, R.H. (2006). Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apcmin mice. FASEB J 20, 506-508. (Pubitemid 46671231)
33. Myzak, M.C., Karplus, P.A., Chung, F.L., and Dashwood, R.H. (2004). A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res 64, 5767-5774. (Pubitemid 39095576)
34. Nian, H., Delage, B., Ho, E., and Dashwood, R.H. (2009). Modulation of histone deacetylase activity by dietary isothiocynates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds. Environ Mol Mutagen 50, 213-221.
35. Osada, H., Tatematsu, Y., Saito, H., Yatabe, Y., Mitsudomi, T., and Takahash, T. (2004). Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer 112, 26-32. (Pubitemid 39249488)
36. Paris, M., Porcelloni, M., Binaschi, M., and Fattori, D. (2008). Histone deacetylase inhibitors: from bench to clinic. J Med Chem 51, 1505-1529. (Pubitemid 351438836)
37. Pasheva, E., Sarov, M., Bidjekov K, et al. (2004). In vitro acetylation of HMGB-1 and-2 proteins by CBP: the role of the acidic tail. Biochemistry 43, 2935-2940. (Pubitemid 38327825)
38. Patnaik, A., Rowinsky, E.K., Villalona, M.A., Hammond, L.A., Britten, C.D., Siu, L.L., Goetz, A., Felton, S.A., Burton, S., Valone, F.H., and Eckhardt, S.G. (2002). A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid in patients with advanced solid malignancies. Clin Cancer Res 8, 2142-2148. (Pubitemid 34753584)
39. Piekarz, R., and Bates S. (2004). A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Design 10, 2289-2298. (Pubitemid 38855037)
40. Pili, R., Kruszewski, M.P., Hager, B.W., Lantz, J., and Carducci MA. (2001). Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 61, 1477-1485. (Pubitemid 34292576)
41. Rasheed, W.K., Johnstone, R.W., and Prince, H.M. (2007). Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 16, 659-678. (Pubitemid 46729100)
42. Rountree, M.R., Bachman, K.E., and Baylin, S.B. (2000). DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet 25, 269-277. (Pubitemid 30437311)
43. Taunton, J., Hassig, C.A., and Schreiber, S.L. (1996). A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272, 408-411. (Pubitemid 26138177)
44. Vega, R.B., Matsuda, K., Oh, J., Barbosa, A.C., Yang, X., Meadows, E., McAnally, J., Pomajzl, C., Shelton, J.M., Richardson, J.A., Karsenty, G., and Olson, E.N. (2004). Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119, 555-566. (Pubitemid 39482354)
45. Weichert, W., Roske1, A., Gekeler, V., Beckers, T., Stephan, C., Jung, K., Fritzsche, F.R., Niesporek, S., Denkert, C., Dietel, M., and Kristiansen, G. (2008). Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98, 604-610. (Pubitemid 351214528)
46. Wilson, A.J., Byun, D.S., Popova, N., Murray, L.B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L.H., and Mariadason, J.M. (2006). Histone deacetylase 3 (HDAC3) and other Class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon Cancer. J Biol Chem 281, 13548-13558. (Pubitemid 43855268)
47. Witt, O., Deubzer, H.E., Milde, T., and Oehme, I. (2009). HDAC family: what are the cancer relevant targets? Cancer Lett 277, 8-21.
48. Zhang, Q., Chakravarty, S., Ghersi, D., Zeng, L., Plotnikov, A.N., and Sanchez, R. (2010). Biochemical Profiling of Histone Binding Selectivity of the Yeast Bromodomain family. PLoS One 5, 1.
49. Zhang, Y., Kwon, S., Yamaguchi, T., Cubizolles, F., Rousseaux, S., Kneissel, M., Cao, C., Li, N., Cheng, H.L., Chua, K., Lombard, D., Mizeracki, A., Matthias, G., Alt, F.W., Khochbin, S., and Matthias, P. (2008). Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 28, 1688-1701.